TD-HW431026

Iladatuzumab(TD-HW431026) is a research-grade recombinant antibody targetingCD79B. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P40259

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

DCDS0780A, MCDS0593A, RO7032005, 1906205-76-2

Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination with other therapy regimens are also under evaluation for previously untreated DLBCL patients.

Detects CD79β/CD79B in indirect ELISAs.　　|　SDS-PAGE for Research Grade Iladatuzumab　　|　Western blot analysis was performed using anti-CD79β/CD79B monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant human CD79β/CD79B (Catalog No:TD-HW431011)　　|　Flow-cytometry using APC anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer. ### Flow-cytometry using PE anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer. ### Flow-cytometry using FITC anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

For research use only. Not suitable for clinical or therapeutic use.